Incidental focal 18F-FDG uptake in the pituitary gland: clinical significance and differential diagnostic criteria

J Nucl Med. 2011 Apr;52(4):547-50. doi: 10.2967/jnumed.110.083733. Epub 2011 Mar 18.

Abstract

The purpose of this study was to identify the incidence and clinical significance of incidental pituitary uptake on whole-body (18)F-FDG PET/CT.

Methods: We evaluated 13,145 consecutive subjects who underwent (18)F-FDG PET/CT. The final diagnosis of pathologic or physiologic uptake was based on brain MRI and follow-up PET scanning. Receiver-operating-characteristic curve analysis was performed to determine an optimal cutoff for detecting pathologic uptake.

Results: We found that 107 (0.8%) subjects showed incidental pituitary uptake. In 29 of 71 subjects with the final diagnosis, the pituitary uptake was pathologic: macroadenomas (n = 21), microadenomas (n = 5), and malignancy (n = 3). When a maximum standardized uptake value of 4.1 was used as an optimal criterion for detecting pathologic uptake, the diagnostic sensitivity, specificity, and accuracy were 96.6%, 88.1%, and 91.5%, respectively.

Conclusion: Although incidental pituitary uptake is an unusual finding, the degree of (18)F-FDG accumulation is helpful in identifying pathologic pituitary lesions that warrant further diagnostic evaluation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Brain / diagnostic imaging
  • Diagnosis, Differential
  • Female
  • Fluorodeoxyglucose F18* / pharmacokinetics
  • Humans
  • Male
  • Middle Aged
  • Pituitary Gland / diagnostic imaging*
  • Pituitary Gland / metabolism*
  • Pituitary Neoplasms / diagnostic imaging*
  • Pituitary Neoplasms / metabolism*
  • Positron-Emission Tomography
  • ROC Curve
  • Radiopharmaceuticals* / pharmacokinetics
  • Tomography, Emission-Computed
  • Whole-Body Counting

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18